Liver biopsy in modern clinical practice: a pediatric point-of-view.

Department of Pediatrics, Morgan Stanley Children's Hospital of New York, NY, USA.
Advances in anatomic pathology (Impact Factor: 3.22). 07/2012; 19(4):250-62. DOI: 10.1097/PAP.0b013e31825c6a20
Source: PubMed

ABSTRACT Liver biopsy remains the foundation of evaluation and management of liver disease in children, although the role of the liver biopsy is changing with development of alternative methods of diagnosis and advancement of hepatic imaging techniques. The indications for liver biopsy are evolving as current knowledge of etiologies, noninvasive biomarker alternatives, and treatment options in pediatric liver disease are expanding. The procedure can often be complicated in children by technical difficulties, cost, and smaller specimen size. Communication and partnership of clinicians with pathologists experienced in pediatric liver diseases are essential. DNA sequencing, novel imaging modalities, noninvasive biomarkers of fibrosis and apoptosis, proteomics, and genome-wide association studies offer potential alternative methods for evaluation of liver disease in children. This review presents specific indications, considerations, methods, complications, contraindications, and alternatives for pediatric liver biopsy.

  • [Show abstract] [Hide abstract]
    ABSTRACT: to characterize the clinical, laboratory, and anthropometric profile of a sample of Brazilian patients with glycogen storage disease type I managed at an outpatient referral clinic for inborn errors of metabolism.
    Jornal de Pediatria 07/2014; · 0.94 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Die nichtalkoholische Fettleberkrankheit (NAFLK) ist in den Industrieländern eine der häufigsten chronischen Leberkrankheiten und die dritthäufigste Indikation zur Lebertransplantation in den Vereinigten Staaten. Sie kommt im Kindes- und Erwachsenenalter vor und gilt als hepatische Manifestation des metabolischen Syndroms. Klinische Verläufe haben die formale Sequenz von NAFLK über Steatohepatitis zu Leberzirrhose zweifelsfrei bewiesen. Patienten mit manifester Steatohepatitis haben ein größeres Risiko für das Auftreten kardiovaskulärer Erkrankungen und ein erhöhtes Krebserkrankungsrisiko. Die Leberbiopsie ist unverändert der Goldstandard für die Diagnosesicherung. Abstract Non-alcoholic fatty liver disease (NAFLD) has become one of the most common chronic liver diseases in developed countries. It is the third most common indication for liver transplantation in the United States. NAFLD affects children and adults. It is considered to be the hepatic manifestation of metabolic syndrome. Clinical case histories validated the progression of NFALD to steatohepatitis and frank liver cirrhosis. Patients with steatohepatitis are at increased risk to suffer from cardiovascular disease and even cancer. Liver biopsy currently remains the gold standard for the diagnosis.
    Der Gastroenterologe 11/2013; 8(6):517-524.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Inherited liver diseases are a group of metabolic and genetic defects that typically cause early chronic liver involvement. Most are due to a defect of an enzyme/transport protein that alters a metabolic pathway and exerts a pathogenic role mainly in the liver. The prevalence is variable, but most are rare pathologies. We review the pathophysiology of such diseases and the diagnostic contribution of laboratory tests, focusing on the role of molecular genetics. In fact, thanks to recent advances in genetics, molecular analysis permits early and specific diagnosis for most disorders and helps to reduce the invasive approach of liver biopsy.
    International journal of hepatology. 01/2014; 2014:713754.